Tg Therapeutics (TGTX) Current Deferred Revenue (2012 - 2026)
Tg Therapeutics' (TGTX) quarterly Current Deferred Revenue came in at $17.2 million in Q1 2026, up 0.65% year-on-year from $17.1 million in Q1 2025, and down 19.04% quarter-over-quarter from $21.2 million in Q4 2025.
Tg Therapeutics (TGTX) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Tg Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $17.2 million for Q1 2026.
- On a quarterly basis, Current Deferred Revenue rose 0.65% year-over-year to $17.2 million in Q1 2026; TTM through Mar 2026 was $17.2 million, a 0.65% increase from a year earlier, with the FY2025 full-year figure at $21.2 million, up 86.03% from the prior year.
- Current Deferred Revenue eased to $17.2 million in Q1 2026 per TGTX's latest filing, from $21.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $26.4 million in Q3 2025 and bottomed at $152000.0 in Q4 2023.
- The 5-year median for Current Deferred Revenue is $3.4 million (2024), against an average of $8.4 million.
- Across the five-year window, Current Deferred Revenue slumped 69.6% in 2023 and surged 7409.21% in 2024, its largest moves.
- Year by year, Current Deferred Revenue stood at $500000.0 in 2022, then slumped by 69.6% to $152000.0 in 2023, then jumped by 7409.21% to $11.4 million in 2024, then surged by 86.03% to $21.2 million in 2025, then retreated by 19.04% to $17.2 million in 2026.
- Per Business Quant, the three latest TGTX Current Deferred Revenue figures stand at $17.2 million (Q1 2026), $21.2 million (Q4 2025), and $26.4 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Tg Therapeutics | 8.88 Bn | 8.80 Bn | 171.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.19 Mn |
| Dec 31, 2025 | 21.23 Mn |
| Sep 30, 2025 | 26.40 Mn |
| Jun 30, 2025 | 23.91 Mn |
| Mar 31, 2025 | 17.08 Mn |
| Dec 31, 2024 | 11.41 Mn |
| Sep 30, 2024 | 9.09 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 3.37 Mn |
| Dec 31, 2023 | 152,000.00 |
| Sep 30, 2023 | 6.90 Mn |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 400,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 600,000.00 |
| Dec 31, 2021 | 600,000.00 |
| Sep 30, 2021 | 600,000.00 |
| Jun 30, 2021 | 700,000.00 |